Nazia chaudhary | Drug Repurposing | Young Scientist Award

Dr Nazia chaudhary, ACTREC, TMC, India

Dr. Nazia Chaudhary is a distinguished cancer researcher with a Ph.D. focused on pathways promoting tumorigenesis and therapy resistance upon Plakophilin 3 loss . Her academic journey includes notable projects on protease-producing thermophiles and mitochondrial function . She co-holds patents on Lipocalin-2 antibodies and has published extensively in high-impact journals , including Redox Biology and FEBS Letters. A DST Inspire Faculty Fellow (2023) , she has received numerous awards, including the Vaishno Endowment Prize and Mahindra Talent Scholarships . Dr. Chaudhary’s impactful work has been presented globally , including at Cold Spring Harbor Laboratory, New York.

Publication Profile

Orcid

Academic Project

Dr. Nazia Chaudhary is an accomplished researcher with a Ph.D. focused on the project “Characterization of pathways that promote tumorigenesis, radio, and chemo-resistance upon Plakophilin 3 loss.” She worked on isolating and characterizing protease and antimicrobial-producing thermophiles from Ganeshpuri hot springs at St. Xavier’s College, Mumbai (Jan-Apr 2015). Additionally, she contributed to the external project “MKT1 Dependent Regulation of Mitochondrial Function” at Tata Institute of Fundamental Research (May-Aug 2014). Her EXSP project involved isolating and screening thermophilic Actinomycetes for enzymes with industrial importance. Dr. Chaudhary’s diverse research showcases her expertise in microbiology and biotechnology.

Conference Attended

Dr. Nazia Chaudhary has showcased her research on various esteemed platforms. She presented a poster titled “Screening of Thermophilic Actinomycetes Capable of Producing Enzymes of Industrial Importance” at the Shri Sajjan Gupta Memorial Trophy for Excellence in Biological Science, held on December 11, 2012, at G.N. Khalsa College. Another poster, “Increase in Lipocalin2 Expression Upon Plakophilin3 Loss Confers Chemo and Radioresistance to Tumor Cells,” was presented at the Environmental Mutagen Society of India (EMSI) conference in January 2018 at BARC, Mumbai, and at the prestigious Mechanisms & Models of Cancer meeting in August 2018 at Cold Spring Harbor Laboratory, New York.

Awards and Honors

Dr. Nazia Chaudhary is a distinguished scholar with multiple accolades. She was awarded the prestigious DST Inspire Faculty Award in 2023 and recognized for her research on lipocalin 2 expression and chemo-radiotherapy resistance at the 14th Indo-Australian Biotechnology Conference. She served as a Board of Studies member for Sophia College’s Zoology Department (2018-2021). Throughout her academic journey, she earned various honors, including the Ramidevi Murlidhar Jalan Award , Saifee Education Aid Scholarship , and the Mahindra Search for Talent Scholarship . Her exceptional performance also earned her the Mrs. A. Varghese Prize and several other prestigious scholarships and awards.

Patent

Dr. Nazia Chaudhary, along with Sorab N. Dalal, Manjula Das, Sujan K. Dhar, and Smitha P. K., contributed to the development of “Antibodies Against Lipocalin-2 and Use Thereof.” This groundbreaking research led to two key milestones. The first was the PCT application (PCT/IN2020/051068) with publication no. WO/2021/137254 on July 8, 2021. The second was the Indian patent (DBT Indian Patent no: 202021000274) granted on July 30, 2021, published in the Patent Office journal no. 31/2021. These innovations hold significant potential for medical advancements.

Research Focus

Dr. Nazia Chaudhary’s research focuses on the molecular mechanisms of cancer progression, therapy resistance, and invasion, particularly in triple-negative breast cancer (TNBC) and colorectal cancer. She investigates the role of Lipocalin 2 (LCN2) in regulating cellular processes like focal adhesion formation, actin glutathionylation, and ferroptosis inhibition, which are critical for tumor cell migration and resistance to treatment. Her work explores the interplay between signaling pathways, such as Src activation and glutathione metabolism, to uncover potential vulnerabilities in cancer cells.